FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922487873> ?p ?o ?g. }

• W2922487873 endingPage "626" @default.
• W2922487873 startingPage "626" @default.
• W2922487873 abstract "Abstract Background: Parenteral anticoagulants may improve outcomes in patients with cancer by reducing the risk of venous thromboembolism (VTE) and through a direct anti-tumour effect. Study-level meta-analysis indicates a reduction in VTE and provide moderate certainty that a small survival benefit exists; it is unclear if patients with specific cancers benefit more or less. Utilizing data from randomized controlled trials (RCT), this individual participant data meta-analysis examines the impact of heparin on survival, VTE and major bleeding in oncological patients randomized to low-molecular weight heparin (LMWH) or no LMWH. Methods: We performed a comprehensive systematic search for all RCTS (last search date March 2017) and contacted authors and sponsors to obtain individual participant data of patients with solid cancers and no other indication for prophylactic or therapeutic anticoagulation. We utilized the GRADE approach to evaluate the certainty of evidence and produce an evidence profile. All analyses followed the intention-to-treat principle. We calculated the impact on mortality through multivariable hierarchical models with patient-level variables as fixed effects and a categorical trial variable as a random effect. We adjusted the analysis for age, cancer type and metastasis status. To investigate whether intervention effects vary by predefined subgroups, including type of cancer, we tested interaction terms in the statistical model. Results: A total of 18 RCTs (n=10,041 participants) were eligible for inclusion and we obtained data from 82.4% of the participants (13 RCTs, n=8,278; n=4,139 for LMWH and n=4,139 for no LMWH). The meta-analysis revealed an adjusted relative risk of mortality within one year of 0.99 (95% CI: 0.95, 1.03) and a hazard ratio of 0.97 (95% CI: 0.82, 1.14) after one year. The relative risk for VTE was 0.58 (95% CI: 0.48, 0.71), 0.57 (95% CI: 0.44, 0.74) for symptomatic deep vein thrombosis and 0.58 (95%CI: 0.44, 0.77) for symptomatic pulmonary embolism, separately. For every 1,000 patients treated, approximately 16 fewer would experience symptomatic DVT and 16 fewer would experience any PE. The adjusted relative risk for major bleeding throughout trial duration was 1.24 (95% CI: 0.91, 1.69; P=0.17). Subgroup analysis, by cancer type, of VTE occurrence throughout trial duration identified lung cancer OR=0.52 (95% CI: 0.39, 0.68; P&lt;0.001) and pancreatic cancer OR=0.55 (95% CI: 0.35, 0.88; P=0.01) patients as experiencing the greatest benefit from LMWH treatment. The certainty of the evidence for the outcomes was moderate to high. Conclusion: LMWH reduces risk of VTE without increasing risk of bleeding but does not improve survival across all patients. Funding: Canadian Institutes of Health Research knowledge synthesis grant, KRS 126594 Registration: International Prospective Register for Systematic Reviews (PROSPERO), CRD42013003526. Disclosures Schünemann: Canadian Institutes of Health Research: Research Funding. Crowther: Alexion: Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Boehringer Ingelheim: Speakers Bureau; Leo Pharma: Research Funding; Pfizer: Honoraria; Portola: Consultancy; Shinogi: Consultancy. Macbeth: Pfizer: Other: Provision of Dalteparin for FRAGMATIC trial; Cancer Research UK: Research Funding. Griffiths: Pfizer: Consultancy, Other: Comment: I run an academic clinical trials unit, have received educational/investigator intiated research grants from companies that make these heparin agents. As consultant &gt; 3 years ago, advised Pfizer on clinical trial designs unrelated to this study., Research Funding. Van Es: Pfizer: Employment, Other: Comment: Dr. van Es reports personal fees from Pfizer as a member of their advisory board. These fees are unrelated to this project.. Streiff: Roche: Research Funding; Portola: Research Funding; Janssen Scientific Affairs, LLC: Consultancy, Research Funding; CSL Behring: Consultancy, Research Funding. Ageno: BMS-Pfizer: Consultancy, Honoraria; Bayer AG: Consultancy, Honoraria, Research Funding; Boehringer Ingelheim: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria. Bozas: PharmaMar: Honoraria. McBane: Bristol Myers Squibb: Other: Research grant for cancer associated VTE. Maraveyas: Bayer: Other: Personal fees and conference attendance; Bristol-Myers Squibb: Other: Grants and personal fees; Leo Pharma: Other: Grants, personal fees and conference attendance; Pfizer: Other: Personal fees. Loprinzi: Bristol Myers: Other: Grant - unrelated to this project; Janssen: Other: Grant - unrelated to this project." @default.
• W2922487873 created "2019-03-22" @default.
• W2922487873 creator A5003655272 @default.
• W2922487873 creator A5006886614 @default.
• W2922487873 creator A5008767553 @default.
• W2922487873 creator A5009413838 @default.
• W2922487873 creator A5009969222 @default.
• W2922487873 creator A5010705038 @default.
• W2922487873 creator A5013491140 @default.
• W2922487873 creator A5019888759 @default.
• W2922487873 creator A5022791522 @default.
• W2922487873 creator A5031717153 @default.
• W2922487873 creator A5035786262 @default.
• W2922487873 creator A5038341180 @default.
• W2922487873 creator A5041615321 @default.
• W2922487873 creator A5041931668 @default.
• W2922487873 creator A5042290277 @default.
• W2922487873 creator A5043376437 @default.
• W2922487873 creator A5050586204 @default.
• W2922487873 creator A5051516231 @default.
• W2922487873 creator A5053386657 @default.
• W2922487873 creator A5058636562 @default.
• W2922487873 creator A5060816944 @default.
• W2922487873 creator A5061726857 @default.
• W2922487873 creator A5063712891 @default.
• W2922487873 creator A5066647668 @default.
• W2922487873 creator A5067414470 @default.
• W2922487873 creator A5068180312 @default.
• W2922487873 creator A5070474680 @default.
• W2922487873 creator A5071868716 @default.
• W2922487873 creator A5073060840 @default.
• W2922487873 creator A5075406786 @default.
• W2922487873 creator A5079941141 @default.
• W2922487873 creator A5081041579 @default.
• W2922487873 creator A5081775695 @default.
• W2922487873 creator A5081971224 @default.
• W2922487873 creator A5084659683 @default.
• W2922487873 creator A5084918409 @default.
• W2922487873 creator A5085582583 @default.
• W2922487873 creator A5087431865 @default.
• W2922487873 creator A5090496730 @default.
• W2922487873 date "2017-12-07" @default.
• W2922487873 modified "2023-10-18" @default.
• W2922487873 title "An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients" @default.
• W2922487873 doi "https://doi.org/10.1182/blood.v130.suppl_1.626.626" @default.
• W2922487873 hasPublicationYear "2017" @default.
• W2922487873 type Work @default.
• W2922487873 sameAs 2922487873 @default.
• W2922487873 citedByCount "4" @default.
• W2922487873 countsByYear W29224878732018 @default.
• W2922487873 countsByYear W29224878732019 @default.
• W2922487873 countsByYear W29224878732022 @default.
• W2922487873 crossrefType "journal-article" @default.
• W2922487873 hasAuthorship W2922487873A5003655272 @default.
• W2922487873 hasAuthorship W2922487873A5006886614 @default.
• W2922487873 hasAuthorship W2922487873A5008767553 @default.
• W2922487873 hasAuthorship W2922487873A5009413838 @default.
• W2922487873 hasAuthorship W2922487873A5009969222 @default.
• W2922487873 hasAuthorship W2922487873A5010705038 @default.
• W2922487873 hasAuthorship W2922487873A5013491140 @default.
• W2922487873 hasAuthorship W2922487873A5019888759 @default.
• W2922487873 hasAuthorship W2922487873A5022791522 @default.
• W2922487873 hasAuthorship W2922487873A5031717153 @default.
• W2922487873 hasAuthorship W2922487873A5035786262 @default.
• W2922487873 hasAuthorship W2922487873A5038341180 @default.
• W2922487873 hasAuthorship W2922487873A5041615321 @default.
• W2922487873 hasAuthorship W2922487873A5041931668 @default.
• W2922487873 hasAuthorship W2922487873A5042290277 @default.
• W2922487873 hasAuthorship W2922487873A5043376437 @default.
• W2922487873 hasAuthorship W2922487873A5050586204 @default.
• W2922487873 hasAuthorship W2922487873A5051516231 @default.
• W2922487873 hasAuthorship W2922487873A5053386657 @default.
• W2922487873 hasAuthorship W2922487873A5058636562 @default.
• W2922487873 hasAuthorship W2922487873A5060816944 @default.
• W2922487873 hasAuthorship W2922487873A5061726857 @default.
• W2922487873 hasAuthorship W2922487873A5063712891 @default.
• W2922487873 hasAuthorship W2922487873A5066647668 @default.
• W2922487873 hasAuthorship W2922487873A5067414470 @default.
• W2922487873 hasAuthorship W2922487873A5068180312 @default.
• W2922487873 hasAuthorship W2922487873A5070474680 @default.
• W2922487873 hasAuthorship W2922487873A5071868716 @default.
• W2922487873 hasAuthorship W2922487873A5073060840 @default.
• W2922487873 hasAuthorship W2922487873A5075406786 @default.
• W2922487873 hasAuthorship W2922487873A5079941141 @default.
• W2922487873 hasAuthorship W2922487873A5081041579 @default.
• W2922487873 hasAuthorship W2922487873A5081775695 @default.
• W2922487873 hasAuthorship W2922487873A5081971224 @default.
• W2922487873 hasAuthorship W2922487873A5084659683 @default.
• W2922487873 hasAuthorship W2922487873A5084918409 @default.
• W2922487873 hasAuthorship W2922487873A5085582583 @default.
• W2922487873 hasAuthorship W2922487873A5087431865 @default.
• W2922487873 hasAuthorship W2922487873A5090496730 @default.
• W2922487873 hasConcept C121608353 @default.
• W2922487873 hasConcept C126322002 @default.
• W2922487873 hasConcept C141071460 @default.
• W2922487873 hasConcept C143998085 @default.
• W2922487873 hasConcept C168563851 @default.
• W2922487873 hasConcept C177713679 @default.

• next